Water-Soluble Concentrate Composition Low-Temperature Crystallization

The patent introduces a specific co-solvent (compound of formula I) as an intermediary substance between the phenoxy acid salt and the adjuvant. This co-solvent mediates the interaction to prevent crystallization while allowing the adjuvant to maintain its wettability-enhancing function. The co-solvent acts as a protective intermediary that stabilizes the formulation at low temperatures without compromising the adjuvant's effectiveness.

The patent changes the chemical composition parameters of the formulation by incorporating a specific co-solvent with defined molecular structure (formula I). This parameter change - the addition of the co-solvent at controlled concentrations - fundamentally alters the physical chemistry of the system to prevent crystallization while preserving adjuvant functionality. The co-solvent modifies the solution properties to maintain stability across a wider temperature range.

The patent applies parameter changes by introducing a co-solvent that specifically interacts with high concentrations of phenoxy acid salt to prevent crystallization. The co-solvent's molecular structure (formula I) is designed to maintain solubility at high active ingredient concentrations, allowing the formulation to achieve high bioefficacy while remaining stable at low temperatures. This parameter change enables high concentration formulations without the usual crystallization risk.

The patent creates a composite formulation system combining phenoxy acid salt, adjuvant, and a specifically designed co-solvent (formula I). This composite material approach allows the components to work synergistically - the co-solvent provides the structural framework that prevents crystallization while the adjuvant provides wettability enhancement, and the high concentration of active ingredient provides bioefficacy. The composite nature of the formulation resolves the contradiction between concentration and stability.